Lexington, MA — January 15, 2026 — Leads & Copy — Agenus Inc. has finalized its strategic collaboration with Zydus Lifesciences Ltd., designed to accelerate the global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program, the company said.
According to the company, the collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation.
Under the terms of the agreement, Zydus gains exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories.
The collaboration, initially announced on June 3, 2025, includes a $75 million cash payment to Agenus for the transfer of biologics manufacturing facilities in Emeryville and Berkeley, California. Zydus also made a $16 million equity investment in Agenus, purchasing approximately 2.1 million shares of Agenus common stock at $7.50 per share.
Agenus is also eligible for up to $50 million in contingent milestone payments tied to BOT+BAL production orders, and will receive a 5% royalty on net sales in India and Sri Lanka.
Dr. Garo Armen Ph.D., Chairman and Chief Executive Officer of Agenus, stated that the collaboration with Zydus strengthens the company’s balance sheet and secures dedicated U.S. manufacturing capacity. He added that the company’s focus in 2026 includes advancing its Phase 3 program, broadening paid patient access, and progressing toward regulatory submission supported by clinical datasets in MSS colorectal cancer.
In 2025, the BOT+BAL combination demonstrated a two-year overall survival rate of 42% and a median overall survival of 21 months in a cohort of 123 patients with third-line or later microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. Agenus, in collaboration with Canadian Cancer Trials Group (CCTG) has initiated the global BATTMAN Phase 3 trial, with sites activated and prepared to enroll patients.
Following the closing, the Emeryville and Berkeley, California biologics manufacturing facilities will be transferred to Zydus under a newly formed subsidiary named Zylidac Bio LLC. Agenus has secured committed manufacturing capacity at these U.S. sites to support BOT+BAL supply needs for their clinical trials, global access programs and future commercialization.
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited., said that Zylidac Bio LLC will provide biologicals manufacturing sites offering CDMO services to biopharmaceutical companies globally. He added that it supports the evolving landscape of biological product manufacturing in the U.S., which prioritizes secure, domestic, and high-quality supply chains for advanced therapies and offers a critical, compliant solution for global innovators and allows for a localized supply chain.
Agenus was advised by Porrima Ltd and Biotech Value Advisors (BVA) on partner selection, transaction structure, and negotiations.
Agenus is an immuno-oncology company targeting cancer with a pipeline of immunological agents. The company is headquartered in Lexington, MA.
Agenus is committed to responsible patient access to investigational medicines through clinical trials and regulatory-authorized early-access mechanisms. In France, BOT+BAL is available only through the ANSM-authorized AAC framework under a nationally validated protocol, with full government reimbursement for eligible patients treated in hospital.
Until marketing authorization is granted, BOT+BAL is accessible only through clinical trials including the planned Phase 3 BATTMAN trial in refractory MSS colorectal cancer and authorized early access mechanisms where permitted and available under each country’s regulatory framework.
Agenus, in collaboration with the Canadian Cancer Trials Group (CCTG), is initiating a global Phase 3 registrational trial evaluating botensilimab (BOT) plus balstilimab (BAL) versus best supportive care (BSC) in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer. The trial will enroll approximately 800 patients across more than 100 sites in Canada, France, Australia, and New Zealand.
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. In France, botensilimab is accessible only through the ANSM-authorized AAC framework when used as BOT+BAL under the national protocol described above.
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. In France, balstilimab is accessible only through the ANSM-authorized AAC framework when used as BOT+BAL under the national protocol described above.
Contact: Agenus Inc.
Source: Agenus